Benjamin J Marsh1, Jina Sinskey1, Elizabeth L Whitlock1, Marla B Ferschl2, Mark D Rollins3. 1. Department of Anesthesia and Perioperative Care, University of California, San Francisco, California, USA. 2. Department of Anesthesia and Perioperative Care, University of California, San Francisco, California, USA, marla.ferschl@ucsf.edu. 3. Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Abstract
INTRODUCTION: Open fetal repair of myelomeningocele (MMC) is an option for prenatally diagnosed spina bifida. Historically, high-dose volatile anesthetic was used for uterine relaxation but is associated with fetal cardiovascular depression. We examined the impact of administering a supplemental remifentanil infusion on the concentration of inhaled anesthetic required for intraoperative uterine relaxation. METHODS: We retrospectively analyzed 22 consecutive patients who underwent open fetal MMC repair with desflurane anesthesia from 2014 to 2018. The anesthetic protocol was modified to include high-dose opioid with remifentanil in 2016. We examined intraoperative end-tidal desflurane concentrations, vasopressor use, incidence of umbilical artery Doppler abnormalities, and incidence of preterm labor and delivery. RESULTS: Patients (n = 11) who received desflurane and remifentanil (Des/Remi) were compared to patients (n = 11) who received desflurane (Des) alone. Intraoperatively, the maximum end-tidal desflurane required to maintain uterine relaxation was lower in the Des/Remi group (7.9 ± 2.2% vs. 13.1 ± 1.2%, p < 0.001). The mean phenylephrine infusion rate was also lower in the Des/Remi group (36 ± 14 vs. 53 ± 10 mcg/min, p = 0.004). DISCUSSION: Use of opioid with supplemental remifentanil was associated with lower volatile anesthetic dosing and decreased vasopressor use; fetal outcomes were not different. Remifentanil may allow for less volatile anesthetic use while maintaining adequate uterine relaxation.
INTRODUCTION: Open fetal repair of myelomeningocele (MMC) is an option for prenatally diagnosed spina bifida. Historically, high-dose volatile anesthetic was used for uterine relaxation but is associated with fetal cardiovascular depression. We examined the impact of administering a supplemental remifentanil infusion on the concentration of inhaled anesthetic required for intraoperative uterine relaxation. METHODS: We retrospectively analyzed 22 consecutive patients who underwent open fetal MMC repair with desflurane anesthesia from 2014 to 2018. The anesthetic protocol was modified to include high-dose opioid with remifentanil in 2016. We examined intraoperative end-tidal desflurane concentrations, vasopressor use, incidence of umbilical artery Doppler abnormalities, and incidence of preterm labor and delivery. RESULTS: Patients (n = 11) who received desflurane and remifentanil (Des/Remi) were compared to patients (n = 11) who received desflurane (Des) alone. Intraoperatively, the maximum end-tidal desflurane required to maintain uterine relaxation was lower in the Des/Remi group (7.9 ± 2.2% vs. 13.1 ± 1.2%, p < 0.001). The mean phenylephrine infusion rate was also lower in the Des/Remi group (36 ± 14 vs. 53 ± 10 mcg/min, p = 0.004). DISCUSSION: Use of opioid with supplemental remifentanil was associated with lower volatile anesthetic dosing and decreased vasopressor use; fetal outcomes were not different. Remifentanil may allow for less volatile anesthetic use while maintaining adequate uterine relaxation.
Authors: Jina L Sinskey; Mark D Rollins; Elizabeth Whitlock; Anita J Moon-Grady; Lan Vu; John R Feiner; Marla B Ferschl Journal: Fetal Diagn Ther Date: 2017-08-22 Impact factor: 2.587
Authors: Rebecca A Fanning; Jason P McMorrow; Deirdre P Campion; Michael F Carey; John J O'Connor Journal: Eur J Pharmacol Date: 2012-10-07 Impact factor: 4.432
Authors: S M Kinsella; B Carvalho; R A Dyer; R Fernando; N McDonnell; F J Mercier; A Palanisamy; A T H Sia; M Van de Velde; A Vercueil Journal: Anaesthesia Date: 2017-11-01 Impact factor: 6.955
Authors: Marc Van de Velde; Dominique Van Schoubroeck; Liesbeth E Lewi; Marco A E Marcus; Jacques C Jani; Carlo Missant; An Teunkens; Jan A Deprest Journal: Anesth Analg Date: 2005-07 Impact factor: 5.108
Authors: N Scott Adzick; Elizabeth A Thom; Catherine Y Spong; John W Brock; Pamela K Burrows; Mark P Johnson; Lori J Howell; Jody A Farrell; Mary E Dabrowiak; Leslie N Sutton; Nalin Gupta; Noel B Tulipan; Mary E D'Alton; Diana L Farmer Journal: N Engl J Med Date: 2011-02-09 Impact factor: 91.245
Authors: Judith A Smith; Roopali V Donepudi; Pedro S Argoti; Anita L Giezentanner; Ranu Jain; Noemi Boring; Elisa Garcia; Kenneth J Moise Journal: Front Pharmacol Date: 2017-01-24 Impact factor: 5.810